首页 > 最新文献

Almanac of Clinical Medicine最新文献

英文 中文
Comparison of in-hospital and long-term mortality and assessment of their predictors in patients with myocardial infarction and unstable angina 心肌梗死合并不稳定型心绞痛患者住院死亡率与长期死亡率的比较及其预测因素的评估
Pub Date : 2023-06-22 DOI: 10.18786/2072-0505-2023-51-013
A. Shchinova, A. Potekhina, Y. Dolgusheva, Yuliya E. Efremova, A. Osokina, A. Filatova, E. V. Sorokin, I. I. Shestova, S. I. Provatorov
Background: The extent of myocardial damage largely determines both in-hospital and long-term mortality in patients with acute coronary syndrome. According to the literature, the in-hospital and long-term mortality rates in patients with unstable angina (UA) are lower than those in the patients with myocardial infarction (MI). Aim: To evaluate the in-hospital and long-term mortality rates and their predictors in patients undergoing in-patient treatment for acute coronary syndrome (MI and UA) in the regional cardiovascular center with the service territory of 1 million persons. Materials and methods: This retrospective registry study enrolled 1130 patients (715 [63.3%] men, 415 [36.7%] women) who were treated for UA and MI in the regional cardiovascular center in 2019. Based on the discharge diagnosis, the patients were divided into two groups: patients with MI (n = 766) and those with an UA episode (n = 364). The in-hospital and delayed mortality rates, as well as their predictors, were analyzed in both groups. The mean duration of the follow-up was 17.8 3.6 months. Results: The in-hospital mortality in patients with confirmed MI was 11.1% (85 patients) versus 0.27% (1 patient) in the UA patients (p 0.001). The independent predictors of in-hospital mortality in MI patients were a decreased left ventricular ejection fraction (LV EF) (odds ratio (OR) 0.9021, 95% confidence interval (CI) 0.82090.9914, p = 0.0324), chronic kidney disease C3a and above (OR 9.3205, 95% CI 2.670632.5283, p = 0.0005), and the extension of coronary involvement at coronary angiography (OR 1.3526, 95% CI 1.06670.0127, p = 0.0127). The long-term mortality in MI patients was 10.4% (72 patients) with no significant difference from that in UA patients (9.9%, 36 patients, p = 0.76). The independent predictors of long-term mortality after MI were older age (OR 1.12, 95% CI 1.011.22, p = 0.0052), chronic kidney disease C3a and above (OR 2.3375, 95% CI 1.13924.7963, p = 0.0206), decreased EF (OR 0.8895, 95% CI 0.730.99, p = 0.0364), atrial fibrillation on admission (OR 3.1462, 95% CI 1.35107.3268, p = 0.0079), and diabetes mellitus (OR 2.3163, 95% CI 1.25524.2744, p = 0.0072). In the UA patients, the predictors of the long-term mortality were a decrease in LV EF (OR 0.9139, 95% CI 0.86830.9619, p = 0.0006) and in blood hemoglobin level (OR 0.9729, 95% CI 0.95440.9917, p = 0.0050). Conclusion: The in-hospital mortality in UA patients is lower than that in MI patients, with comparable long-term mortality. This indicates the need of active follow-up of the patients with past UA, irrespective of the endovascular assessment and intervention.
背景:心肌损伤程度在很大程度上决定了急性冠脉综合征患者的住院和长期死亡率。文献显示,不稳定型心绞痛(UA)患者的住院死亡率和远期死亡率均低于心肌梗死(MI)患者。目的:评价100万地区心血管中心急性冠脉综合征(MI和UA)住院患者的住院死亡率和长期死亡率及其预测因素。材料和方法:本回顾性登记研究纳入了2019年在区域心血管中心接受UA和MI治疗的1130例患者(男性715例[63.3%],女性415例[36.7%])。根据出院诊断,将患者分为两组:MI患者(n = 766)和UA发作患者(n = 364)。对两组患者的住院死亡率和延迟死亡率及其预测因素进行了分析。平均随访时间17.8 - 3.6个月。结果:确诊心肌梗死患者的住院死亡率为11.1%(85例),而UA患者的住院死亡率为0.27%(1例)(p 0.001)。心肌梗死患者住院死亡率的独立预测因子为左室射血分数(LV EF)降低(优势比0.9021,95%可信区间(CI) 0.82090.9914, p = 0.0324)、慢性肾脏疾病C3a及以上(OR 9.3205, 95% CI 2.670632.5283, p = 0.0005)、冠状动脉造影时冠状动脉受累范围扩大(OR 1.3526, 95% CI 1.06670.0127, p = 0.0127)。心肌梗死患者的长期死亡率为10.4%(72例),与UA患者的长期死亡率(9.9%,36例,p = 0.76)无显著差异。心肌梗死后长期死亡率的独立预测因子为年龄较大(OR 1.12, 95% CI 1.011.22, p = 0.0052)、慢性肾脏疾病C3a及以上(OR 2.3375, 95% CI 1.13924.7963, p = 0.0206)、EF下降(OR 0.8895, 95% CI 0.730.99, p = 0.0364)、入院时房颤(OR 3.1462, 95% CI 1.35107.3268, p = 0.0079)和糖尿病(OR 2.3163, 95% CI 1.25524.2744, p = 0.0072)。在UA患者中,长期死亡率的预测因子为LV EF降低(OR 0.9139, 95% CI 0.86830.9619, p = 0.0006)和血血红蛋白水平降低(OR 0.9729, 95% CI 0.95440.9917, p = 0.0050)。结论:UA患者住院死亡率低于心肌梗死患者,长期死亡率相当。这表明需要对既往UA患者进行积极随访,而不考虑血管内评估和干预。
{"title":"Comparison of in-hospital and long-term mortality and assessment of their predictors in patients with myocardial infarction and unstable angina","authors":"A. Shchinova, A. Potekhina, Y. Dolgusheva, Yuliya E. Efremova, A. Osokina, A. Filatova, E. V. Sorokin, I. I. Shestova, S. I. Provatorov","doi":"10.18786/2072-0505-2023-51-013","DOIUrl":"https://doi.org/10.18786/2072-0505-2023-51-013","url":null,"abstract":"Background: The extent of myocardial damage largely determines both in-hospital and long-term mortality in patients with acute coronary syndrome. According to the literature, the in-hospital and long-term mortality rates in patients with unstable angina (UA) are lower than those in the patients with myocardial infarction (MI). \u0000Aim: To evaluate the in-hospital and long-term mortality rates and their predictors in patients undergoing in-patient treatment for acute coronary syndrome (MI and UA) in the regional cardiovascular center with the service territory of 1 million persons. \u0000Materials and methods: This retrospective registry study enrolled 1130 patients (715 [63.3%] men, 415 [36.7%] women) who were treated for UA and MI in the regional cardiovascular center in 2019. Based on the discharge diagnosis, the patients were divided into two groups: patients with MI (n = 766) and those with an UA episode (n = 364). The in-hospital and delayed mortality rates, as well as their predictors, were analyzed in both groups. The mean duration of the follow-up was 17.8 3.6 months. \u0000Results: The in-hospital mortality in patients with confirmed MI was 11.1% (85 patients) versus 0.27% (1 patient) in the UA patients (p 0.001). The independent predictors of in-hospital mortality in MI patients were a decreased left ventricular ejection fraction (LV EF) (odds ratio (OR) 0.9021, 95% confidence interval (CI) 0.82090.9914, p = 0.0324), chronic kidney disease C3a and above (OR 9.3205, 95% CI 2.670632.5283, p = 0.0005), and the extension of coronary involvement at coronary angiography (OR 1.3526, 95% CI 1.06670.0127, p = 0.0127). The long-term mortality in MI patients was 10.4% (72 patients) with no significant difference from that in UA patients (9.9%, 36 patients, p = 0.76). The independent predictors of long-term mortality after MI were older age (OR 1.12, 95% CI 1.011.22, p = 0.0052), chronic kidney disease C3a and above (OR 2.3375, 95% CI 1.13924.7963, p = 0.0206), decreased EF (OR 0.8895, 95% CI 0.730.99, p = 0.0364), atrial fibrillation on admission (OR 3.1462, 95% CI 1.35107.3268, p = 0.0079), and diabetes mellitus (OR 2.3163, 95% CI 1.25524.2744, p = 0.0072). In the UA patients, the predictors of the long-term mortality were a decrease in LV EF (OR 0.9139, 95% CI 0.86830.9619, p = 0.0006) and in blood hemoglobin level (OR 0.9729, 95% CI 0.95440.9917, p = 0.0050). \u0000Conclusion: The in-hospital mortality in UA patients is lower than that in MI patients, with comparable long-term mortality. This indicates the need of active follow-up of the patients with past UA, irrespective of the endovascular assessment and intervention.","PeriodicalId":7638,"journal":{"name":"Almanac of Clinical Medicine","volume":"294 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2023-06-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"73525638","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Efficacy and safety of molnupiravir in adult outpatients with COVID-19 莫那匹拉韦治疗COVID-19成人门诊患者的疗效和安全性
Pub Date : 2023-06-22 DOI: 10.18786/2072-0505-2023-51-014
N. Pshenichnaya, K. Omarova, L. Balykova, K. Zaslavskaya, D. N. Zemskov, A. V. Taganov, P. A. Belyy, A. Gorelov, D. Pushkar
Background: One of the basic principles for the treatment of COVID-19 patients is the early initiation of etiotropic therapy. The evidence base for assessment of the efficacy and safety of antivirals for COVID-19 continues to expand with new clinical trials. One of the promising etiotropic medications is molnupiravir. Aim: To evaluate the efficacy and safety of molnupiravir (Esperavir) in outpatients with COVID-19. Materials and methods: This randomized comparative open-label clinical study was conducted from December 1, 2021 to March 11, 2022 in 12 research centers in the Russian Federation. The study involved 240 outpatients with mild and moderate COVID-19. The mean age of patients was 43.5 years; 70,0% (168/240) of the patients had comorbidities, mainly obesity grade II and arterial hypertension. The outpatients were treated with molnupiravir (Esperavir, PROMOMED RUS LLC, Russia) in 4 capsules 200 mg twice daily (every 12 hours), with the single dose being 800 mg and the daily dose 1600 mg. Duration of treatment was 5 days. The patients were followed up for 28 days. The patients in the standard treatment group (n = 120) received antiviral therapy recommended for outpatients by the provisional guidelines effective at the time of the study. Pathogenetic and symptomatic therapy in both groups was comparable. Results: The results of the clinical study in 240 outpatients with mild or moderate COVID-19 showed that molnupiravir at a dose of 800 mg twice daily for 5 days significantly reduced (by 4-hold at days 1415 of the follow-up) the risk of disease progression to more severe course, compared with the standard therapy group (2.5% (3/120) and 10.0% (12/120) of patients; p = 0.0149.) By days 67 of the follow-up, the virus had been eliminated in 71.67% of the patients treated with the study drug and only in 58.3% (70/120) of the patients in the standard therapy group. Complete clinical recovery at days 67 was achieved in 19.2% (23/120) of the patients in the molnupiravir group, compared to 5.8% (7/120) in the standard therapy group. Compared to the standard therapy, treatment with molnupiravir also significantly reduced the frequency and severity of the disease symptoms, such as cough and change in odor or taste perception over the last 24 hours, already at 67 days after the start of treatment. Molnupiravir treatment was well tolerated, most adverse events were mild. There were no cases of drug withdrawal or dose modification of the study drug due to adverse events. Conclusion: The results of the clinical study of antiviral agent molnupiravir (Esperavir) have proven its benefits over standard therapy in outpatients with mild and moderate COVID-19 in terms of the disease worsening risk reduction and hospitalization, the rate of viral elimination, the changes in symptoms severity over time, improvement of the patients general status and clinical condition and reduction of COVID-19 complications both in patients without and with risk factors for sev
背景:早期开始致病因治疗是治疗COVID-19患者的基本原则之一。随着新的临床试验的开展,评估COVID-19抗病毒药物疗效和安全性的证据基础不断扩大。一种很有前途的致病因药物是莫努匹拉韦。目的:评价莫硝吡韦(埃斯佩拉韦)治疗新型冠状病毒肺炎(COVID-19)门诊患者的疗效和安全性。材料和方法:这项随机比较开放标签临床研究于2021年12月1日至2022年3月11日在俄罗斯联邦的12个研究中心进行。该研究涉及240名轻中度COVID-19门诊患者。患者平均年龄43.5岁;70.0%(168/240)的患者存在合并症,主要为II级肥胖和动脉高血压。门诊患者接受莫努匹拉韦(埃斯佩拉韦,promed RUS LLC,俄罗斯)4粒胶囊,200 mg,每日2次(每12小时一次),单次剂量为800 mg,每日剂量为1600 mg。疗程为5 d。随访28 d。标准治疗组(n = 120)患者接受研究时有效的临时指南推荐的门诊患者抗病毒治疗。两组的发病和对症治疗具有可比性。结果:240例轻中度COVID-19门诊患者的临床研究结果显示,与标准治疗组(2.5%(3/120)和10.0%(12/120)的患者相比,莫那匹拉韦剂量为800 mg,每日2次,连续5天显著降低(随访第1415天为4天)疾病进展为更严重病程的风险;P = 0.0149。)到随访第67天,71.67%接受研究药物治疗的患者的病毒被消除,而标准治疗组只有58.3%(70/120)的患者被消除。molnupiravir组患者在第67天完全临床恢复的比例为19.2%(23/120),而标准治疗组为5.8%(7/120)。与标准疗法相比,molnupiravir治疗也显著降低了疾病症状的频率和严重程度,如咳嗽和气味或味觉感知的变化,在过去24小时内,已经在治疗开始后的67天。莫努匹拉韦治疗耐受性良好,大多数不良事件轻微。没有因不良事件而停药或调整研究药物剂量的病例。结论:抗病毒药物莫努皮拉韦(埃斯佩拉韦)的临床研究结果证明,在无和有严重结局危险因素的患者中,在疾病恶化风险降低和住院率、病毒消除率、症状严重程度随时间的变化、患者一般状态和临床状况的改善以及COVID-19并发症的减少方面,莫努皮拉韦在轻中度COVID-19门诊患者中优于标准治疗。该研究的结果表明,莫努匹拉韦在COVID-19患者中具有良好的安全性。
{"title":"Efficacy and safety of molnupiravir in adult outpatients with COVID-19","authors":"N. Pshenichnaya, K. Omarova, L. Balykova, K. Zaslavskaya, D. N. Zemskov, A. V. Taganov, P. A. Belyy, A. Gorelov, D. Pushkar","doi":"10.18786/2072-0505-2023-51-014","DOIUrl":"https://doi.org/10.18786/2072-0505-2023-51-014","url":null,"abstract":"Background: One of the basic principles for the treatment of COVID-19 patients is the early initiation of etiotropic therapy. The evidence base for assessment of the efficacy and safety of antivirals for COVID-19 continues to expand with new clinical trials. One of the promising etiotropic medications is molnupiravir. \u0000Aim: To evaluate the efficacy and safety of molnupiravir (Esperavir) in outpatients with COVID-19. \u0000Materials and methods: This randomized comparative open-label clinical study was conducted from December 1, 2021 to March 11, 2022 in 12 research centers in the Russian Federation. The study involved 240 outpatients with mild and moderate COVID-19. The mean age of patients was 43.5 years; 70,0% (168/240) of the patients had comorbidities, mainly obesity grade II and arterial hypertension. The outpatients were treated with molnupiravir (Esperavir, PROMOMED RUS LLC, Russia) in 4 capsules 200 mg twice daily (every 12 hours), with the single dose being 800 mg and the daily dose 1600 mg. Duration of treatment was 5 days. The patients were followed up for 28 days. The patients in the standard treatment group (n = 120) received antiviral therapy recommended for outpatients by the provisional guidelines effective at the time of the study. Pathogenetic and symptomatic therapy in both groups was comparable. \u0000Results: The results of the clinical study in 240 outpatients with mild or moderate COVID-19 showed that molnupiravir at a dose of 800 mg twice daily for 5 days significantly reduced (by 4-hold at days 1415 of the follow-up) the risk of disease progression to more severe course, compared with the standard therapy group (2.5% (3/120) and 10.0% (12/120) of patients; p = 0.0149.) By days 67 of the follow-up, the virus had been eliminated in 71.67% of the patients treated with the study drug and only in 58.3% (70/120) of the patients in the standard therapy group. Complete clinical recovery at days 67 was achieved in 19.2% (23/120) of the patients in the molnupiravir group, compared to 5.8% (7/120) in the standard therapy group. Compared to the standard therapy, treatment with molnupiravir also significantly reduced the frequency and severity of the disease symptoms, such as cough and change in odor or taste perception over the last 24 hours, already at 67 days after the start of treatment. Molnupiravir treatment was well tolerated, most adverse events were mild. There were no cases of drug withdrawal or dose modification of the study drug due to adverse events. \u0000Conclusion: The results of the clinical study of antiviral agent molnupiravir (Esperavir) have proven its benefits over standard therapy in outpatients with mild and moderate COVID-19 in terms of the disease worsening risk reduction and hospitalization, the rate of viral elimination, the changes in symptoms severity over time, improvement of the patients general status and clinical condition and reduction of COVID-19 complications both in patients without and with risk factors for sev","PeriodicalId":7638,"journal":{"name":"Almanac of Clinical Medicine","volume":"16 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2023-06-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"73048034","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Identification of Reed-Berezovsky-Sternberg cells in lymphatic nodes in classic Hodgkin's lymphoma by flow cytometry: a clinical case series 流式细胞术鉴定经典霍奇金淋巴瘤淋巴结中的Reed-Berezovsky-Sternberg细胞:临床病例系列
Pub Date : 2023-06-22 DOI: 10.18786/2072-0505-2023-51-015
F. М. Abbasbeyli, A. Fedenko, Pervin A. Zeynalova, Тatyana Y. Mushkarina, A. Melnikova, L. Grivtsova
Despite their B cell origin, Reed-Berezovsky-Sternberg tumor cells (RBS) in classic Hodgkin's lymphoma (cHL) demonstrate an absolutely unique phenotype. Immunohistochemistry of RBS cells is positive for CD15 antigen in most of cases, CD30, PAX-5; they do not express the T cell antigen CD3, В cell CD19, and in most cases are negative for the B cell antigen CD20, as well as for common leukocyte antigen CD45. Taking into account such unequivocal immunophenotype, RBS cells can be identified by multiparameter flow cytometry. Thus, J.R. Fromm et al. (2006, 2014) have convincingly shown the possibility to identify RBS cells in a puncture and/or biopsy sample of lymphatic nodes in cHL and were of the fair opinion that such rather simple and reproducible technique as flow cytometry could be an additional diagnostic instrument in cHL. We have tested the technique proposed by J.R. Fromm et al. for the assessment of lymphatic node involvement in cHL and used 8 to 10-parameter flow cytometry for detection RBS cells in cHL in 8 biopsy samples of a lymphatic node, and confirmed the feasibility to identify RBS cells by high performance flow cytometry. We also performed morphological and immunohistochemical assessment of the biopsy samples of lymphatic nodes from patients with suspected cHL. The study included clinical cases with immunohistochemically confirmed cHL (n = 8), and the control samples were from those with other diagnoses than Hodgkin's lymphoma. In all cases of cHL we found RBS cells. In future we plan to analyze larger case samples by flow cytometry.
尽管它们起源于B细胞,但经典霍奇金淋巴瘤(cHL)中的Reed-Berezovsky-Sternberg肿瘤细胞(RBS)表现出绝对独特的表型。大多数RBS细胞免疫组化CD15抗原、CD30、PAX-5阳性;它们不表达T细胞抗原CD3, В细胞CD19,并且在大多数情况下对B细胞抗原CD20和常见的白细胞抗原CD45呈阴性。考虑到这种明确的免疫表型,RBS细胞可以通过多参数流式细胞术进行鉴定。因此,J.R. Fromm等人(2006,2014)令人信服地证明了在cHL的淋巴结穿刺和/或活检样本中识别RBS细胞的可能性,并公平地认为,像流式细胞术这样相当简单且可重复的技术可以作为cHL的额外诊断工具。我们测试了J.R. Fromm等人提出的评估cHL淋巴结累及的技术,并在8个淋巴结活检样本中使用8 ~ 10参数流式细胞术检测cHL中的RBS细胞,证实了高效流式细胞术鉴定RBS细胞的可行性。我们还对疑似cHL患者的淋巴结活检样本进行了形态学和免疫组织化学评估。该研究包括免疫组织化学证实的cHL临床病例(n = 8),对照样本来自霍奇金淋巴瘤以外的其他诊断。在所有cHL病例中,我们都发现了RBS细胞。未来我们计划用流式细胞术分析更大的病例样本。
{"title":"Identification of Reed-Berezovsky-Sternberg cells in lymphatic nodes in classic Hodgkin's lymphoma by flow cytometry: a clinical case series","authors":"F. М. Abbasbeyli, A. Fedenko, Pervin A. Zeynalova, Тatyana Y. Mushkarina, A. Melnikova, L. Grivtsova","doi":"10.18786/2072-0505-2023-51-015","DOIUrl":"https://doi.org/10.18786/2072-0505-2023-51-015","url":null,"abstract":"Despite their B cell origin, Reed-Berezovsky-Sternberg tumor cells (RBS) in classic Hodgkin's lymphoma (cHL) demonstrate an absolutely unique phenotype. Immunohistochemistry of RBS cells is positive for CD15 antigen in most of cases, CD30, PAX-5; they do not express the T cell antigen CD3, В cell CD19, and in most cases are negative for the B cell antigen CD20, as well as for common leukocyte antigen CD45. Taking into account such unequivocal immunophenotype, RBS cells can be identified by multiparameter flow cytometry. Thus, J.R. Fromm et al. (2006, 2014) have convincingly shown the possibility to identify RBS cells in a puncture and/or biopsy sample of lymphatic nodes in cHL and were of the fair opinion that such rather simple and reproducible technique as flow cytometry could be an additional diagnostic instrument in cHL. \u0000We have tested the technique proposed by J.R. Fromm et al. for the assessment of lymphatic node involvement in cHL and used 8 to 10-parameter flow cytometry for detection RBS cells in cHL in 8 biopsy samples of a lymphatic node, and confirmed the feasibility to identify RBS cells by high performance flow cytometry. We also performed morphological and immunohistochemical assessment of the biopsy samples of lymphatic nodes from patients with suspected cHL. The study included clinical cases with immunohistochemically confirmed cHL (n = 8), and the control samples were from those with other diagnoses than Hodgkin's lymphoma. In all cases of cHL we found RBS cells. In future we plan to analyze larger case samples by flow cytometry.","PeriodicalId":7638,"journal":{"name":"Almanac of Clinical Medicine","volume":"20 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2023-06-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"83497409","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 1
Intraoperative computed tomography perfusion navigation for maximal resection of high grade gliomas: a prospective non-randomized trial 术中计算机断层扫描灌注导航用于最大程度切除高级别胶质瘤:一项前瞻性非随机试验
Pub Date : 2023-06-16 DOI: 10.18786/2072-0505-2023-51-012
R. Talybov, T. N. Trofimova, V. Mochalov, I. V. Shvetsov, V. V. Spasennikov
Background: The main purpose of surgery for glioblastoma is to ensure the maximally possible cytoreduction. Computed tomography perfusion imaging has non-invasive tools for assessment of tumor blood flow and allows for visualization of the tumor borders and its most malignant zones. Aim: To evaluate the efficacy of intraoperative computed tomography perfusion navigation (ICTPN) during surgery for high grade gliomas. Materials and methods: This prospective non-randomized study included 142 patients (76 men and 66 women) with morphologically verified diagnosis of glioblastoma or diffuse astrocytoma grade 4 (World Health Organization 2021 criteria), who had surgery from 2016 to 2022. The ICTPN-based procedures were performed in 94 patients, with 55 with gross total and 39 with subtotal tumor resection. The control group included 48 patients with non-ICTPN-based surgical procedures. All patients were treated with standard adjuvant chemoradiation therapy. The efficacy of surgery was assessed every 3 months. The study endpoint was any tumor progression. The duration of the follow-up was 15 months. Baseline and contrast-enhanced preoperative imaging and postoperative follow-up assessments were performed with a 3T magnetic resonance imaging scanner (General Electric Discovery W750). ICTPN was done with a 32 slice computed tomography scanner (Toshiba Aquilion LB). Results: In the totally resected ICTPN group, the mean duration of the relapse-free period was 13.05 months; the relapse-free survival at 6 and 12 months was 92 and 55%, respectively (p 0.001). These results were significantly better than those in the subtotally resected ICTPN patients (8.98 months, 66 and 9%, respectively; log rank test for Kaplan-Meier curves, p 0.001) and in non-ICTPN patients (5.81 months, 23 and 0%, respectively, log rank test, p 0.001). Conclusion: ICTPN enables a more objective assessment of the tumor borders and the extent of its resection, as well as relapse-free survival benefits for the patients.
背景:胶质母细胞瘤手术的主要目的是确保最大可能的细胞减少。计算机断层扫描灌注成像具有评估肿瘤血流的非侵入性工具,并允许肿瘤边界及其最恶性区域的可视化。目的:评价术中计算机断层扫描灌注导航(ICTPN)在高级别胶质瘤手术中的应用效果。材料和方法:这项前瞻性非随机研究纳入了142例患者(76名男性和66名女性),经形态学证实诊断为胶质母细胞瘤或弥漫性星形细胞瘤4级(世界卫生组织2021年标准),于2016年至2022年接受手术。94例患者接受了基于ictpn的手术,其中55例肿瘤全切除,39例肿瘤次全切除。对照组包括48例采用非ictpn手术的患者。所有患者均接受标准辅助放化疗。每3个月评估一次手术疗效。研究终点是任何肿瘤进展。随访时间为15个月。使用3T磁共振成像扫描仪(General Electric Discovery W750)进行基线和对比增强术前成像和术后随访评估。采用32层计算机断层扫描仪(Toshiba Aquilion LB)完成ICTPN。结果:全切除ICTPN组平均无复发时间为13.05个月;6个月和12个月无复发生存率分别为92%和55% (p 0.001)。这些结果明显优于次全切除的ICTPN患者(分别为8.98个月、66%和9%;Kaplan-Meier曲线的log rank检验,p 0.001)和非ictpn患者(分别为5.81个月,23%和0%,log rank检验,p 0.001)。结论:ICTPN能够更客观地评估肿瘤边界和切除程度,以及患者的无复发生存益处。
{"title":"Intraoperative computed tomography perfusion navigation for maximal resection of high grade gliomas: a prospective non-randomized trial","authors":"R. Talybov, T. N. Trofimova, V. Mochalov, I. V. Shvetsov, V. V. Spasennikov","doi":"10.18786/2072-0505-2023-51-012","DOIUrl":"https://doi.org/10.18786/2072-0505-2023-51-012","url":null,"abstract":"Background: The main purpose of surgery for glioblastoma is to ensure the maximally possible cytoreduction. Computed tomography perfusion imaging has non-invasive tools for assessment of tumor blood flow and allows for visualization of the tumor borders and its most malignant zones. \u0000Aim: To evaluate the efficacy of intraoperative computed tomography perfusion navigation (ICTPN) during surgery for high grade gliomas. \u0000Materials and methods: This prospective non-randomized study included 142 patients (76 men and 66 women) with morphologically verified diagnosis of glioblastoma or diffuse astrocytoma grade 4 (World Health Organization 2021 criteria), who had surgery from 2016 to 2022. The ICTPN-based procedures were performed in 94 patients, with 55 with gross total and 39 with subtotal tumor resection. The control group included 48 patients with non-ICTPN-based surgical procedures. All patients were treated with standard adjuvant chemoradiation therapy. The efficacy of surgery was assessed every 3 months. The study endpoint was any tumor progression. The duration of the follow-up was 15 months. Baseline and contrast-enhanced preoperative imaging and postoperative follow-up assessments were performed with a 3T magnetic resonance imaging scanner (General Electric Discovery W750). ICTPN was done with a 32 slice computed tomography scanner (Toshiba Aquilion LB). \u0000Results: In the totally resected ICTPN group, the mean duration of the relapse-free period was 13.05 months; the relapse-free survival at 6 and 12 months was 92 and 55%, respectively (p 0.001). These results were significantly better than those in the subtotally resected ICTPN patients (8.98 months, 66 and 9%, respectively; log rank test for Kaplan-Meier curves, p 0.001) and in non-ICTPN patients (5.81 months, 23 and 0%, respectively, log rank test, p 0.001). \u0000Conclusion: ICTPN enables a more objective assessment of the tumor borders and the extent of its resection, as well as relapse-free survival benefits for the patients.","PeriodicalId":7638,"journal":{"name":"Almanac of Clinical Medicine","volume":"11 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2023-06-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"79483573","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Hemorrhage into a somatotropinoma аs a first reason for examination of a patient with previously undiagnosed acromegaly and papillary thyroid cancer 生长肌瘤出血是对先前未确诊的肢端肥大症和甲状腺乳头状癌患者进行检查的首要原因
Pub Date : 2023-06-03 DOI: 10.18786/2072-0505-2023-51-011
G. Nurullina, Igor N. Pushkarev, E. Pigarova, N. V. Latkina, G. I. Akhmadullina
Pituitary apoplexy is a rare acute condition that can be caused by hemorrhage into the pituitary adenoma or its infarction. This is accompanied by severe headache, nausea, vomiting, photophobia, visual and oculomotor disorders, loss of consciousness, and can also lead to a decrease in the production of a number of hormones by the pituitary gland, i.e. hypopituitarism. We present a clinical case of a 42-year female patient with previously undiagnosed acromegaly and papillary thyroid cancer. The reason for the examination was clinical symptoms of pituitary apoplexy. Right hemithyroidectomy with central and lateral lymphadenectomy was performed for her papillary thyroid cancer, followed by radioactive iodine therapy due to an increased risk of cancer progression. Hemorrhage into the pituitary adenoma in this patient has led to panhypopituitarism and remission of acromegaly. Insulin-like growth factor 1 and growth hormone levels during oral glucose tolerance test were within the reference values, which made the diagnosis of acromegaly challenging.
垂体中风是一种罕见的急性疾病,可由垂体腺瘤出血或其梗死引起。伴有严重的头痛、恶心、呕吐、畏光、视觉和动眼病、意识丧失,还可导致脑垂体分泌的一些激素减少,即垂体功能减退症。我们报告一个42岁的女性患者,先前未确诊肢端肥大症和甲状腺乳头状癌。检查的原因是垂体中风的临床症状。她的乳头状甲状腺癌行右半甲状腺切除术并中央和外侧淋巴结切除术,随后由于癌症进展的风险增加而接受放射性碘治疗。该患者垂体腺瘤出血导致全垂体功能减退,肢端肥大症缓解。口服糖耐量试验时胰岛素样生长因子1和生长激素水平均在参考值范围内,对肢端肥大症的诊断具有挑战性。
{"title":"Hemorrhage into a somatotropinoma аs a first reason for examination of a patient with previously undiagnosed acromegaly and papillary thyroid cancer","authors":"G. Nurullina, Igor N. Pushkarev, E. Pigarova, N. V. Latkina, G. I. Akhmadullina","doi":"10.18786/2072-0505-2023-51-011","DOIUrl":"https://doi.org/10.18786/2072-0505-2023-51-011","url":null,"abstract":"Pituitary apoplexy is a rare acute condition that can be caused by hemorrhage into the pituitary adenoma or its infarction. This is accompanied by severe headache, nausea, vomiting, photophobia, visual and oculomotor disorders, loss of consciousness, and can also lead to a decrease in the production of a number of hormones by the pituitary gland, i.e. hypopituitarism. We present a clinical case of a 42-year female patient with previously undiagnosed acromegaly and papillary thyroid cancer. The reason for the examination was clinical symptoms of pituitary apoplexy. Right hemithyroidectomy with central and lateral lymphadenectomy was performed for her papillary thyroid cancer, followed by radioactive iodine therapy due to an increased risk of cancer progression. Hemorrhage into the pituitary adenoma in this patient has led to panhypopituitarism and remission of acromegaly. Insulin-like growth factor 1 and growth hormone levels during oral glucose tolerance test were within the reference values, which made the diagnosis of acromegaly challenging.","PeriodicalId":7638,"journal":{"name":"Almanac of Clinical Medicine","volume":"44 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2023-06-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"74680484","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Cognitive impairment and its treatment in patients with multiple sclerosis 多发性硬化症患者的认知障碍及其治疗
Pub Date : 2023-05-24 DOI: 10.18786/2072-0505-2023-51-009
A. Zabirova, I. Bakulin, A. Poydasheva, M. Zakharova, N. Suponeva
Cognitive impairment (CI) is a relatively common manifestation of multiple sclerosis (MS), which can occur with any type of the disease course and activity. The largest CI prevalence and severity are observed in progressive MS. In relapsing-remitting MS the most prominent deterioration of cognitive functions is seen during relapses; however, in some patients it can continue also throughout remission. In a small number of patients CI can be the most significant symptom of the disease; in addition, it sometimes can be the only clinical feature of the relapse. Despite this, in clinical practice CI remains out of the focus of attention, and is not evaluated when assessing the disease severity and/or activity, while CI is not included into EDSS. Nonetheless, a number of specialized neuropsychological tests and batteries has been developed recently, which can be used for both screening and detailed assessment of CI in MS, as well as for assessment of its changes over time. CI has a negative impact on MS patients' quality of life, their social interactions, daily and occupational activities. The influence of disease-modifying agents on CI has been poorly investigated; however, there is evidence that they can reduce the degree of CI. The optimal choice of pathogenetic treatment in patients with CI remains understudied. There is no convincing evidence of the effectiveness of symptomatic pharmacological treatment of CI in MS, and cognitive rehabilitation is the only approach with confirmed effectiveness. Considering the limitations of this technique (its availability, quite a big number of sessions), there is a need to search for other methods to increase its efficacy, including non-invasive neuromodulation (in particular, transcranial direct current stimulation or transcranial magnetic stimulation). This article is focused on a brief review of the main diagnostic methods of CI in MS, its pathogenetic and symptomatic treatment, and cognitive rehabilitation techniques, as well as on the results of the studies on non-invasive neuromodulation.
认知障碍(CI)是多发性硬化症(MS)的一种相对常见的表现,它可以发生在任何类型的病程和活动中。在复发缓解型MS中,认知功能的最显著恶化出现在复发期间;然而,在一些患者中,它也可以持续整个缓解期。在少数患者中,CI可能是该疾病最显著的症状;此外,它有时可能是复发的唯一临床特征。尽管如此,在临床实践中CI仍然不是关注的焦点,在评估疾病严重程度和/或活动时不进行评估,而CI也未纳入EDSS。尽管如此,最近已经开发了一些专门的神经心理学测试和电池,可用于筛选和详细评估多发性硬化症中的CI,以及评估其随时间的变化。CI对MS患者的生活质量、社会交往、日常和职业活动均有负面影响。疾病调节剂对CI的影响研究甚少;然而,有证据表明它们可以降低CI的程度。CI患者的最佳致病治疗选择仍未得到充分研究。没有令人信服的证据表明对症药物治疗MS CI的有效性,认知康复是唯一确认有效的方法。考虑到该技术的局限性(其可用性,相当多的会话),需要寻找其他方法来提高其疗效,包括无创神经调节(特别是经颅直流电刺激或经颅磁刺激)。本文就多发性硬化症CI的主要诊断方法、发病机制、对症治疗、认知康复技术以及无创神经调节的研究成果作一综述。
{"title":"Cognitive impairment and its treatment in patients with multiple sclerosis","authors":"A. Zabirova, I. Bakulin, A. Poydasheva, M. Zakharova, N. Suponeva","doi":"10.18786/2072-0505-2023-51-009","DOIUrl":"https://doi.org/10.18786/2072-0505-2023-51-009","url":null,"abstract":"Cognitive impairment (CI) is a relatively common manifestation of multiple sclerosis (MS), which can occur with any type of the disease course and activity. The largest CI prevalence and severity are observed in progressive MS. In relapsing-remitting MS the most prominent deterioration of cognitive functions is seen during relapses; however, in some patients it can continue also throughout remission. In a small number of patients CI can be the most significant symptom of the disease; in addition, it sometimes can be the only clinical feature of the relapse. Despite this, in clinical practice CI remains out of the focus of attention, and is not evaluated when assessing the disease severity and/or activity, while CI is not included into EDSS. Nonetheless, a number of specialized neuropsychological tests and batteries has been developed recently, which can be used for both screening and detailed assessment of CI in MS, as well as for assessment of its changes over time. \u0000CI has a negative impact on MS patients' quality of life, their social interactions, daily and occupational activities. The influence of disease-modifying agents on CI has been poorly investigated; however, there is evidence that they can reduce the degree of CI. The optimal choice of pathogenetic treatment in patients with CI remains understudied. There is no convincing evidence of the effectiveness of symptomatic pharmacological treatment of CI in MS, and cognitive rehabilitation is the only approach with confirmed effectiveness. Considering the limitations of this technique (its availability, quite a big number of sessions), there is a need to search for other methods to increase its efficacy, including non-invasive neuromodulation (in particular, transcranial direct current stimulation or transcranial magnetic stimulation). This article is focused on a brief review of the main diagnostic methods of CI in MS, its pathogenetic and symptomatic treatment, and cognitive rehabilitation techniques, as well as on the results of the studies on non-invasive neuromodulation.","PeriodicalId":7638,"journal":{"name":"Almanac of Clinical Medicine","volume":"21 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2023-05-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"88591702","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Left ventricular diastolic function in adult patients with an atrial septal defect and its age-dependent changes over time after transcatheter closure of the defect 房间隔缺损的成年患者左室舒张功能及其经导管关闭缺损后随时间的年龄依赖性变化
Pub Date : 2023-05-17 DOI: 10.18786/2072-0505-2023-51-008
I. Kovalchuk, I. R. Rafaeli, V. A. Kryukov, A. Rogatova, A. V. Azarov, S. A. Kurnosov, D. G. Ioseliani
Background: There are no echocardiographic (echoCG) criteria to predict whether adult patients with an atrial septal defect (ASD) will develop post-procedural left ventricular (LV) failure after the defect closure. Aim: To evaluate the LV diastolic function before and after the intervention in ASD patients depending on their age and, based on this, to identify potential echoCG risk factors for the development of acute heart failure immediately after the ASD closure. Materials and methods: This retrospective study included 69 patients with the mean age of 44.2 14.5 years and 57 (82.6%) being women. The patients were divided into 2 age groups: group 1 included 39 (56.5%) patients aged 18 to 49 years (mean SD, 35.4 9.4 years) and group 2, 30 (43.5%) patients aged 50 to 74 years (mean SD, 60.1 6.1 years). The characteristics of the ASD, heart chambers and LV diastolic function were assessed with transthoracic and transesophageal echoCG. The indexed indicators of the left atrial (LA) and LV volumes were measured before the intervention and in the postoperative period and compared. LV diastolic function was assessed by the e lateral (determined by tissue Doppler imaging, TDI) and E/e ratio (reference values 10 cm/s and 8, respectively). Results: The indexed LA volume at baseline in the second group was slightly higher than in the first one (27.6 9.8 ml/m2 and 25.4 7.1 ml/m2; p = 0.311), whereas there was no between-group difference in the baseline indexed LV volume parameters (41.8 7.9 ml/m2 and 42.4 8.6 ml/m2, respectively; p = 0.768). Immediately after the closure of the ASD, LV diastolic function deteriorated. In the patients below 50 years of age, this difference was non-significant, despite significant changes in the E/e values (from 7.6 3.6 to 9.9 4.1; p = 0.012). In the second age group, this parameter increased significantly (from 9.2 5.7 to 13.1 4.3, respectively; p = 0.005). The TDI index (e lateral) decreased in both groups: in the group 1, from 11.9 2.5 to 9.1 2.2 (p 0.001) and in the group 2, from 9.3 3.6 to 7.9 1.6 (p = 0.061). Two patients of the elderly group, in whom sings of LV failure were identified immediately after the defect closure, by echoCG showed the lowest TDI values (е lateral) (7.8 and 8.0 cm/sec before closure and 6.4 and 7.0 cm/sec thereafter), as well as the highest values E/e before closure (13.4 and 13.1, respectively). In the long-term (12.5 6.5 months on average), the E/e index decreased in both age groups, compared to that in the early postoperative period, approaching the preoperative parameters (group 50 years of age: 7.6 3.6 9.9 4.1 8.7 4.8, group 50 years of age, 9.2 5.7 13.1 4.3 10.8 5.6). The TDI e indicators also shifted close to their initial values, increasing from 9.1 2.2 to 11.6 1.9 in the group 50 years of age and from 7.9 1.6 to 8.9 2.8 in the group 50 years of age. In the long-term, the LA volume index in both groups was unchanged, compared to its baseline values. The indexed LV end diastolic volum
背景:目前还没有超声心动图(echoCG)标准来预测房间隔缺损(ASD)的成年患者在缺损关闭后是否会发生术后左心室(LV)衰竭。目的:评价不同年龄ASD患者干预前后左室舒张功能,并以此为基础,识别ASD闭锁后立即发生急性心力衰竭的潜在超声心动图危险因素。材料和方法:本回顾性研究纳入69例患者,平均年龄44.2 ~ 14.5岁,女性57例(82.6%)。患者分为2个年龄组:1组18 ~ 49岁39例(56.5%),平均SD为35.4 9.4岁;2组50 ~ 74岁30例(43.5%),平均SD为60.1 6.1岁。应用经胸、经食管超声心动图评估ASD特征、心室及左室舒张功能。测量干预前和术后左房(LA)、左室容积指标,并进行比较。左室舒张功能通过e侧位(通过组织多普勒成像,TDI确定)和e /e比值(参考值分别为10 cm/s和8 cm/s)评估。结果:第二组基线时LA指数体积略高于第一组(27.6 9.8 ml/m2和25.4 7.1 ml/m2;p = 0.311),而基线指标左室容积参数组间无差异(分别为41.8 7.9 ml/m2和42.4 8.6 ml/m2;P = 0.768)。ASD关闭后,左室舒张功能立即恶化。在50岁以下的患者中,尽管E/ E值有显著变化(从7.6 3.6到9.9 4.1;P = 0.012)。在第二年龄组,该参数显著增加(分别从9.2 5.7增加到13.1 4.3;P = 0.005)。两组TDI指数(e侧)均下降:组1从11.9 2.5降至9.1 2.2 (p 0.001),组2从9.3 3.6降至7.9 1.6 (p = 0.061)。2例老年组患者在缺损关闭后立即发现左室衰竭,超声心动图显示TDI值(侧位)最低(关闭前7.8和8.0 cm/sec,关闭后6.4和7.0 cm/sec),关闭前E/ E值最高(分别为13.4和13.1)。长期(平均12.5 6.5个月),两组E/ E指数均较术后早期下降,接近术前参数(50岁组:7.6 3.6 9.9 4.1 8.7 4.8,50岁组:9.2 5.7 13.1 4.3 10.8 5.6)。TDI e指标也向初始值靠拢,50岁组从9.1 2.2上升到11.6 1.9,50岁组从7.9 1.6上升到8.9 2.8。长期来看,两组的LA容积指数与其基线值相比没有变化。两组患者在ASD闭合后1年左室舒张末期容积和舒张末期内径指数均显著升高;但均未超出参考范围,左室收缩功能指标维持在同一水平。结论:经导管ASD闭合后左室容积和左室功能表现出预期的阳性重构。确定ASD关闭后立即发生急性心力衰竭的潜在超声心动图危险因素。ASD患者的早期二尖瓣舒张速度(TDI)低于8.0 cm/sec,左室充盈压力(e /e)高于13。
{"title":"Left ventricular diastolic function in adult patients with an atrial septal defect and its age-dependent changes over time after transcatheter closure of the defect","authors":"I. Kovalchuk, I. R. Rafaeli, V. A. Kryukov, A. Rogatova, A. V. Azarov, S. A. Kurnosov, D. G. Ioseliani","doi":"10.18786/2072-0505-2023-51-008","DOIUrl":"https://doi.org/10.18786/2072-0505-2023-51-008","url":null,"abstract":"Background: There are no echocardiographic (echoCG) criteria to predict whether adult patients with an atrial septal defect (ASD) will develop post-procedural left ventricular (LV) failure after the defect closure. \u0000Aim: To evaluate the LV diastolic function before and after the intervention in ASD patients depending on their age and, based on this, to identify potential echoCG risk factors for the development of acute heart failure immediately after the ASD closure. \u0000Materials and methods: This retrospective study included 69 patients with the mean age of 44.2 14.5 years and 57 (82.6%) being women. The patients were divided into 2 age groups: group 1 included 39 (56.5%) patients aged 18 to 49 years (mean SD, 35.4 9.4 years) and group 2, 30 (43.5%) patients aged 50 to 74 years (mean SD, 60.1 6.1 years). The characteristics of the ASD, heart chambers and LV diastolic function were assessed with transthoracic and transesophageal echoCG. The indexed indicators of the left atrial (LA) and LV volumes were measured before the intervention and in the postoperative period and compared. LV diastolic function was assessed by the e lateral (determined by tissue Doppler imaging, TDI) and E/e ratio (reference values 10 cm/s and 8, respectively). \u0000Results: The indexed LA volume at baseline in the second group was slightly higher than in the first one (27.6 9.8 ml/m2 and 25.4 7.1 ml/m2; p = 0.311), whereas there was no between-group difference in the baseline indexed LV volume parameters (41.8 7.9 ml/m2 and 42.4 8.6 ml/m2, respectively; p = 0.768). Immediately after the closure of the ASD, LV diastolic function deteriorated. In the patients below 50 years of age, this difference was non-significant, despite significant changes in the E/e values (from 7.6 3.6 to 9.9 4.1; p = 0.012). In the second age group, this parameter increased significantly (from 9.2 5.7 to 13.1 4.3, respectively; p = 0.005). The TDI index (e lateral) decreased in both groups: in the group 1, from 11.9 2.5 to 9.1 2.2 (p 0.001) and in the group 2, from 9.3 3.6 to 7.9 1.6 (p = 0.061). Two patients of the elderly group, in whom sings of LV failure were identified immediately after the defect closure, by echoCG showed the lowest TDI values (е lateral) (7.8 and 8.0 cm/sec before closure and 6.4 and 7.0 cm/sec thereafter), as well as the highest values E/e before closure (13.4 and 13.1, respectively). In the long-term (12.5 6.5 months on average), the E/e index decreased in both age groups, compared to that in the early postoperative period, approaching the preoperative parameters (group 50 years of age: 7.6 3.6 9.9 4.1 8.7 4.8, group 50 years of age, 9.2 5.7 13.1 4.3 10.8 5.6). The TDI e indicators also shifted close to their initial values, increasing from 9.1 2.2 to 11.6 1.9 in the group 50 years of age and from 7.9 1.6 to 8.9 2.8 in the group 50 years of age. In the long-term, the LA volume index in both groups was unchanged, compared to its baseline values. The indexed LV end diastolic volum","PeriodicalId":7638,"journal":{"name":"Almanac of Clinical Medicine","volume":"370 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2023-05-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"74549460","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Bile acid dysmetabolism in inflammatory bowel diseases 炎症性肠病中的胆汁酸代谢异常
Pub Date : 2023-05-10 DOI: 10.18786/2072-0505-2023-51-007
D. Kuznetsova, S. Lapin, I. Gubonina
Aim: To summarize the state-of-the-art data on the molecular mechanisms of bile acid (BA) synthesis and absorption, their impaired absorption and receptor-dependent signaling, as well as on the effects of the gut microbiota on BA metabolism in inflammatory bowel diseases (IBD). Key messages: BA malabsorption is one of the relevant mechanisms in the development of diarrhea in IBD. It may occur due to various disorders of the ileum, such as terminal ileitis, ileocolitis or ileocecal resection in Crohn's disease and ileoanal reservoir in ulcerative colitis. Molecular mechanisms of BA malabsorption in IBD are related to a defect in the BA uptake by the apical sodium dependent bile acid transporter (ASBT), as well as to a decrease in the expression of pregnane X receptor (PXR) and farnesoid X receptor (FXR), whose activation by glucocorticoids results in an increase in the BA reabsorption in the ileum and a decrease in hologenic diarrhea. The metabolic profile of luminal BA in IBD is characterized by an increased content of conjugated and 3-OH-sulfated BA and reduced levels of secondary BA. The decrease in the relative abundance of the Lachnospiraceae and Oscillospiraceae spp. in IBD patients leads to a decrease in the efficiency of microbial biotransformation of BA. Changes in the BA metabolic profile in IBD affect the gut microbiota, and impaired interaction with the FXR, PXR, G protein-coupled bile acid receptor (GPBAR1), retinoid-related orphan receptors (RORs) and vitamin D receptor (VDR) results in a pro-inflammatory response and increased intestinal permeability, bacterial translocation, and IBD progression. BA metabolism in IBD-associated primary sclerosing cholangitis (PSC-IBD) is characterized by a significant decrease in the luminal BA pool, and the microbiota composition is remarkable for an increase in the relative abundance of Fusobacterium and Ruminococcus spp., and a decrease in Veillonella, Dorea, Blautia, Lachnospira and Roseburia. Conclusion: Disordered synergistic interplay of BA with intestinal microbiota results in disruption of the ligand-receptor interaction and BA metabolic transformation, which contributes to the activation of the immune system, formation of a vicious circle of chronic inflammation and IBD progression. Further studies into mutual influence of the gut microbiota, BA metabolism and receptor signaling may promote the development of new methods for the diagnosis and treatment of IBD.
目的:综述炎症性肠病(IBD)患者胆汁酸(BA)合成和吸收的分子机制、胆汁酸的吸收受损和受体依赖信号传导以及肠道菌群对BA代谢的影响的最新研究进展。关键信息:BA吸收不良是IBD患者腹泻发生的相关机制之一。它可能是由于回肠的各种疾病引起的,如克罗恩病的终末回肠炎、回肠结肠炎或回肠盲肠切除术,溃疡性结肠炎的回肠贮液。IBD BA吸收不良的分子机制与根尖钠依赖性胆汁酸转运体(ASBT)摄取BA的缺陷有关,也与孕烷X受体(PXR)和法内酯X受体(FXR)表达减少有关,糖皮质激素激活其可导致回肠BA重吸收增加,完全性腹泻减少。肠道内BA在IBD中的代谢特征是共轭BA和3- oh -硫酸酸化BA含量增加,次生BA水平降低。IBD患者体内毛螺科和示波螺科菌相对丰度的降低导致BA微生物转化效率的降低。IBD中BA代谢谱的变化会影响肠道微生物群,并且与FXR、PXR、G蛋白偶联胆汁酸受体(GPBAR1)、类维生素a相关孤儿受体(RORs)和维生素D受体(VDR)的相互作用受损,导致促炎反应和肠道通透性增加、细菌易位和IBD进展。ibd相关性原发性硬化性胆管炎(PSC-IBD)的BA代谢特点是管腔内BA池明显减少,微生物群组成显著,梭杆菌和Ruminococcus spp.的相对丰度增加,Veillonella、Dorea、Blautia、Lachnospira和Roseburia的相对丰度减少。结论:BA与肠道菌群协同作用紊乱,导致配体-受体相互作用和BA代谢转化被破坏,从而激活免疫系统,形成慢性炎症和IBD进展的恶性循环。进一步研究肠道菌群、BA代谢和受体信号之间的相互影响可能会促进IBD诊断和治疗新方法的发展。
{"title":"Bile acid dysmetabolism in inflammatory bowel diseases","authors":"D. Kuznetsova, S. Lapin, I. Gubonina","doi":"10.18786/2072-0505-2023-51-007","DOIUrl":"https://doi.org/10.18786/2072-0505-2023-51-007","url":null,"abstract":"Aim: To summarize the state-of-the-art data on the molecular mechanisms of bile acid (BA) synthesis and absorption, their impaired absorption and receptor-dependent signaling, as well as on the effects of the gut microbiota on BA metabolism in inflammatory bowel diseases (IBD). \u0000Key messages: BA malabsorption is one of the relevant mechanisms in the development of diarrhea in IBD. It may occur due to various disorders of the ileum, such as terminal ileitis, ileocolitis or ileocecal resection in Crohn's disease and ileoanal reservoir in ulcerative colitis. Molecular mechanisms of BA malabsorption in IBD are related to a defect in the BA uptake by the apical sodium dependent bile acid transporter (ASBT), as well as to a decrease in the expression of pregnane X receptor (PXR) and farnesoid X receptor (FXR), whose activation by glucocorticoids results in an increase in the BA reabsorption in the ileum and a decrease in hologenic diarrhea. The metabolic profile of luminal BA in IBD is characterized by an increased content of conjugated and 3-OH-sulfated BA and reduced levels of secondary BA. The decrease in the relative abundance of the Lachnospiraceae and Oscillospiraceae spp. in IBD patients leads to a decrease in the efficiency of microbial biotransformation of BA. Changes in the BA metabolic profile in IBD affect the gut microbiota, and impaired interaction with the FXR, PXR, G protein-coupled bile acid receptor (GPBAR1), retinoid-related orphan receptors (RORs) and vitamin D receptor (VDR) results in a pro-inflammatory response and increased intestinal permeability, bacterial translocation, and IBD progression. BA metabolism in IBD-associated primary sclerosing cholangitis (PSC-IBD) is characterized by a significant decrease in the luminal BA pool, and the microbiota composition is remarkable for an increase in the relative abundance of Fusobacterium and Ruminococcus spp., and a decrease in Veillonella, Dorea, Blautia, Lachnospira and Roseburia. \u0000Conclusion: Disordered synergistic interplay of BA with intestinal microbiota results in disruption of the ligand-receptor interaction and BA metabolic transformation, which contributes to the activation of the immune system, formation of a vicious circle of chronic inflammation and IBD progression. Further studies into mutual influence of the gut microbiota, BA metabolism and receptor signaling may promote the development of new methods for the diagnosis and treatment of IBD.","PeriodicalId":7638,"journal":{"name":"Almanac of Clinical Medicine","volume":"19 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2023-05-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"75758469","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Evaluation of the neutrophil-leukocyte index in patients with cardiac disorders and new coronavirus infection 心脏疾病合并新型冠状病毒感染患者中性粒细胞-白细胞指数的评价
Pub Date : 2023-04-27 DOI: 10.18786/2072-0505-2023-51-006
R. Litvinenko, R. T. Velibekov, S. V. Gaiduk, K. Zhdanov, Darya P. Narolskaya
Background: The neutrophil-leukocyte index (NLI) is an independent predictor of an unfavorable outcome in stable ischemic heart disease, as well as of mortality in patients with acute coronary syndromes and uncontrolled heart failure. A number of studies have shown the informative value of NLI for the prediction of severe course of COVID-19. NLI variability in COVID-19 with comorbid baseline physical diseases and cardiovascular disorders in particular, has not been studied. Aim: To evaluate the clinical value of NLI in hospitalized patients with COVID-19 depending on their concomitant cardiac disorders. Materials and methods: In this retrospective quantitative study we have analyzed the data from medical files of the patients with the diagnosis of new coronavirus infection confirmed by polymerase chain reaction, treated in a specialized in-patient department of infectious diseases in 2020 to 2022. Previously diagnosed cardiac disorders were defined as any past history of these disorders. The results of instrumental and laboratory work-up were assessed before treatment. Results: The analysis included 226 patients with median age of 50.0 (Q1Q3: 42.063.0) years, with 81.4% (n = 184) of them being men. Ninety four (41.6%) patients had no previously diagnosed cardiovascular disorders. Arterial hypertension by the time of admittance was present in 132 (58.4%), ischemic heart disease, in 77 (34.1%), atherosclerotic and/or post-infarct cardiosclerosis, in 82 (36.3%), and chronic heart failure, in 77 (34.1%) of the patients. In the total study group (n = 226) the median NLI was 2.6 (1.574.47). The larger was the volume of the lung involvement (assessed by computed tomography at admittance), the higher was NLI (p = 0.009, Kruskal-Wallis test). There was an association between the NLI value and the degree of respiratory failure (p 0.001, Kruskal-Wallis test). Median NLI in the patients with cardiac disorders (irrespective of their nosology) was significantly higher than that in the patients without any history of cardiovascular problems: 3.30 (2.095.42) versus 1.95 (1.423.62) (p 0.001, Mann-Whitney U-test). We found significant difference in the NLI values for each type of cardiac disorders, compared to that in the patients without history of cardiovascular disorders, including for the patients with arterial hypertension (p 0.001, Kruskal-Wallis test), ischemic heart disease (p 0.001, Mann-Whitney U-test), atherosclerotic cardiosclerosis (p = 0.001, Mann-Whitney U-test), and chronic heart failure (p = 0.040, Kruskal-Wallis test). Conclusion: We have confirmed the contribution of cardiovascular disorders to the course of COVID-19 and the clinical value of NLI as a convenient laboratory marker of the severity of infectious disease.
背景:中性粒细胞-白细胞指数(NLI)是稳定型缺血性心脏病的不利结果的独立预测因子,也是急性冠状动脉综合征和不受控制的心力衰竭患者死亡率的独立预测因子。多项研究表明,NLI对预测COVID-19严重病程具有重要的信息价值。尚未对伴有基线生理疾病和心血管疾病的COVID-19患者NLI变异性进行研究。目的:评价NLI在COVID-19合并心功能障碍住院患者中的临床应用价值。材料与方法:回顾性定量分析某传染病专科住院2020 - 2022年经聚合酶链反应确诊为新型冠状病毒感染患者的病历资料。先前诊断的心脏疾病被定义为这些疾病的任何过去史。治疗前评估仪器检查和实验室检查结果。结果:纳入226例患者,中位年龄50.0岁(Q1Q3: 42.063.0),其中81.4% (n = 184)为男性。94例(41.6%)患者以前没有诊断过心血管疾病。入院时动脉高血压132例(58.4%),缺血性心脏病77例(34.1%),动脉粥样硬化和/或梗死后心脏硬化82例(36.3%),慢性心力衰竭77例(34.1%)。在整个研究组(n = 226)中,NLI中位数为2.6(1.574.47)。肺受累体积越大(通过入院时的计算机断层扫描评估),NLI越高(p = 0.009, Kruskal-Wallis检验)。NLI值与呼吸衰竭程度之间存在相关性(p 0.001, Kruskal-Wallis检验)。心脏疾病患者(不论其分科)的NLI中位数显著高于无心血管病史患者:3.30(2.095.42)对1.95 (1.423.62)(p < 0.001, Mann-Whitney u检验)。我们发现,与无心血管疾病史的患者相比,各种心脏疾病的NLI值有显著差异,包括动脉高血压(p 0.001, Kruskal-Wallis检验)、缺血性心脏病(p 0.001, Mann-Whitney u检验)、动脉粥样硬化性心脏硬化(p = 0.001, Mann-Whitney u检验)和慢性心力衰竭(p = 0.040, Kruskal-Wallis检验)患者。结论:我们确认了心血管疾病对COVID-19病程的贡献,以及NLI作为传染病严重程度的便捷实验室标志物的临床价值。
{"title":"Evaluation of the neutrophil-leukocyte index in patients with cardiac disorders and new coronavirus infection","authors":"R. Litvinenko, R. T. Velibekov, S. V. Gaiduk, K. Zhdanov, Darya P. Narolskaya","doi":"10.18786/2072-0505-2023-51-006","DOIUrl":"https://doi.org/10.18786/2072-0505-2023-51-006","url":null,"abstract":"Background: The neutrophil-leukocyte index (NLI) is an independent predictor of an unfavorable outcome in stable ischemic heart disease, as well as of mortality in patients with acute coronary syndromes and uncontrolled heart failure. A number of studies have shown the informative value of NLI for the prediction of severe course of COVID-19. NLI variability in COVID-19 with comorbid baseline physical diseases and cardiovascular disorders in particular, has not been studied. \u0000Aim: To evaluate the clinical value of NLI in hospitalized patients with COVID-19 depending on their concomitant cardiac disorders. \u0000Materials and methods: In this retrospective quantitative study we have analyzed the data from medical files of the patients with the diagnosis of new coronavirus infection confirmed by polymerase chain reaction, treated in a specialized in-patient department of infectious diseases in 2020 to 2022. Previously diagnosed cardiac disorders were defined as any past history of these disorders. The results of instrumental and laboratory work-up were assessed before treatment. \u0000Results: The analysis included 226 patients with median age of 50.0 (Q1Q3: 42.063.0) years, with 81.4% (n = 184) of them being men. Ninety four (41.6%) patients had no previously diagnosed cardiovascular disorders. Arterial hypertension by the time of admittance was present in 132 (58.4%), ischemic heart disease, in 77 (34.1%), atherosclerotic and/or post-infarct cardiosclerosis, in 82 (36.3%), and chronic heart failure, in 77 (34.1%) of the patients. \u0000In the total study group (n = 226) the median NLI was 2.6 (1.574.47). The larger was the volume of the lung involvement (assessed by computed tomography at admittance), the higher was NLI (p = 0.009, Kruskal-Wallis test). There was an association between the NLI value and the degree of respiratory failure (p 0.001, Kruskal-Wallis test). Median NLI in the patients with cardiac disorders (irrespective of their nosology) was significantly higher than that in the patients without any history of cardiovascular problems: 3.30 (2.095.42) versus 1.95 (1.423.62) (p 0.001, Mann-Whitney U-test). We found significant difference in the NLI values for each type of cardiac disorders, compared to that in the patients without history of cardiovascular disorders, including for the patients with arterial hypertension (p 0.001, Kruskal-Wallis test), ischemic heart disease (p 0.001, Mann-Whitney U-test), atherosclerotic cardiosclerosis (p = 0.001, Mann-Whitney U-test), and chronic heart failure (p = 0.040, Kruskal-Wallis test). \u0000Conclusion: We have confirmed the contribution of cardiovascular disorders to the course of COVID-19 and the clinical value of NLI as a convenient laboratory marker of the severity of infectious disease.","PeriodicalId":7638,"journal":{"name":"Almanac of Clinical Medicine","volume":"23 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2023-04-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"91060060","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
The results of surgery for giant aneurysms of the middle cerebral arteries: a retrospective study 脑中动脉巨动脉瘤的手术治疗结果:回顾性研究
Pub Date : 2023-04-19 DOI: 10.18786/2072-0505-2023-51-005
Yu V Pilipenko, S. Eliava, A. Konovalov, F. Grebenev, B. Barchunov
Background: Surgical treatment of middle cerebral artery (MCA) giant aneurysms is a challenging task. The information on its current principles is rather limited, with the publications based on isolated case reports and small series. Aim: To identify the types of procedures and evaluate the results of surgery in patients with giant MCA aneurysms. Materials and methods: We retrospectively analyzed the data on 55 patients who had undergone surgery for MCA giant aneurysms in the Burdenko Neurosurgery Center from 2010 to 2021. Thereafter 52 patients were followed up for 6 to 120 months (for 53.1 33.7 months on average). Results: The giant MCA aneurysms were located at the M1 segment bifurcation in 33 (60%) patients, within the M1 segment, in 11 (20%), M2 in 7 (12.7%), and M3 and M4 in 4 (7.3%) patients. There were 32 (58.2%) saccular and 23 (41.8%) fusiform aneurysms. Surgical interventions for MCA giant aneurysms included their neck clipping (50.9%, n = 28), clipping with formation of the arterial lumen (3.6%, n = 2), bypass procedures (34.5%, n = 19), wrapping (3.6%, n = 2), and endovascular procedures (7.3%, n = 4). Perioperative worsening of the neurologic status (The Modified Rankin Scale, mRS) was observed in 50.9% (n = 28) of the patients, and the death rate was 1.8% (n = 1). The complete closure of giant aneurysms was achieved in 78.2% (n = 43) of the cases. The long-term outcome was favorable in 76.9% of the patients (40 from 52 available for the follow up). Conclusion: Microsurgical clipping and bypass types of surgery were the most common surgical procedures for the treatment of MCA giant aneurysms. These procedures are technically complex and are associated with a relatively high number of complications. The main directions of future studies could be in the search for new and more precise diagnostic assessment of the collateral circulation in the cortical MCA branches, improvement of the algorithm for the bypass selection, as well as an investigation of the long-term results of endovascular and combined treatments. A thorough long-term postoperative patient follow-up and the possibility of high quality control angiography are of major importance.
背景:大脑中动脉巨动脉瘤的外科治疗是一项具有挑战性的任务。关于其目前原则的资料相当有限,出版物基于孤立的病例报告和小系列。目的:探讨巨中动脉动脉瘤的手术方式及治疗效果。材料和方法:我们回顾性分析2010年至2021年在Burdenko神经外科中心接受MCA巨动脉瘤手术的55例患者的资料。52例患者术后随访6 ~ 120个月,平均53.1 ~ 33.7个月。结果:MCA巨动脉瘤位于M1段分叉处33例(60%),M1段内11例(20%),M2 7例(12.7%),M3和M4 4例(7.3%)。囊状动脉瘤32例(58.2%),梭状动脉瘤23例(41.8%)。MCA巨动脉瘤的手术治疗包括颈夹闭(50.9%,n = 28)、夹闭伴动脉管腔形成(3.6%,n = 2)、旁路手术(34.5%,n = 19)、包裹术(3.6%,n = 2)和血管内手术(7.3%,n = 4)。50.9% (n = 28)的患者围手术期神经功能恶化(改良Rankin量表,mRS)。死亡率1.8% (n = 1), 43例(78.2%)大动脉瘤完全闭合。76.9%的患者(52例随访患者中有40例)的长期预后良好。结论:显微外科夹闭和旁路手术是治疗MCA巨动脉瘤最常用的手术方式。这些手术在技术上是复杂的,并且与相对较高的并发症有关。未来研究的主要方向可能是寻找新的更精确的皮质MCA分支侧支循环诊断评估,改进旁路选择算法,以及研究血管内和联合治疗的长期效果。术后对患者进行彻底的长期随访和进行高质量的血管造影是非常重要的。
{"title":"The results of surgery for giant aneurysms of the middle cerebral arteries: a retrospective study","authors":"Yu V Pilipenko, S. Eliava, A. Konovalov, F. Grebenev, B. Barchunov","doi":"10.18786/2072-0505-2023-51-005","DOIUrl":"https://doi.org/10.18786/2072-0505-2023-51-005","url":null,"abstract":"Background: Surgical treatment of middle cerebral artery (MCA) giant aneurysms is a challenging task. The information on its current principles is rather limited, with the publications based on isolated case reports and small series. \u0000Aim: To identify the types of procedures and evaluate the results of surgery in patients with giant MCA aneurysms. \u0000Materials and methods: We retrospectively analyzed the data on 55 patients who had undergone surgery for MCA giant aneurysms in the Burdenko Neurosurgery Center from 2010 to 2021. Thereafter 52 patients were followed up for 6 to 120 months (for 53.1 33.7 months on average). \u0000Results: The giant MCA aneurysms were located at the M1 segment bifurcation in 33 (60%) patients, within the M1 segment, in 11 (20%), M2 in 7 (12.7%), and M3 and M4 in 4 (7.3%) patients. There were 32 (58.2%) saccular and 23 (41.8%) fusiform aneurysms. Surgical interventions for MCA giant aneurysms included their neck clipping (50.9%, n = 28), clipping with formation of the arterial lumen (3.6%, n = 2), bypass procedures (34.5%, n = 19), wrapping (3.6%, n = 2), and endovascular procedures (7.3%, n = 4). Perioperative worsening of the neurologic status (The Modified Rankin Scale, mRS) was observed in 50.9% (n = 28) of the patients, and the death rate was 1.8% (n = 1). The complete closure of giant aneurysms was achieved in 78.2% (n = 43) of the cases. The long-term outcome was favorable in 76.9% of the patients (40 from 52 available for the follow up). \u0000Conclusion: Microsurgical clipping and bypass types of surgery were the most common surgical procedures for the treatment of MCA giant aneurysms. These procedures are technically complex and are associated with a relatively high number of complications. The main directions of future studies could be in the search for new and more precise diagnostic assessment of the collateral circulation in the cortical MCA branches, improvement of the algorithm for the bypass selection, as well as an investigation of the long-term results of endovascular and combined treatments. A thorough long-term postoperative patient follow-up and the possibility of high quality control angiography are of major importance.","PeriodicalId":7638,"journal":{"name":"Almanac of Clinical Medicine","volume":"13 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2023-04-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"74595411","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 1
期刊
Almanac of Clinical Medicine
全部 Acc. Chem. Res. ACS Applied Bio Materials ACS Appl. Electron. Mater. ACS Appl. Energy Mater. ACS Appl. Mater. Interfaces ACS Appl. Nano Mater. ACS Appl. Polym. Mater. ACS BIOMATER-SCI ENG ACS Catal. ACS Cent. Sci. ACS Chem. Biol. ACS Chemical Health & Safety ACS Chem. Neurosci. ACS Comb. Sci. ACS Earth Space Chem. ACS Energy Lett. ACS Infect. Dis. ACS Macro Lett. ACS Mater. Lett. ACS Med. Chem. Lett. ACS Nano ACS Omega ACS Photonics ACS Sens. ACS Sustainable Chem. Eng. ACS Synth. Biol. Anal. Chem. BIOCHEMISTRY-US Bioconjugate Chem. BIOMACROMOLECULES Chem. Res. Toxicol. Chem. Rev. Chem. Mater. CRYST GROWTH DES ENERG FUEL Environ. Sci. Technol. Environ. Sci. Technol. Lett. Eur. J. Inorg. Chem. IND ENG CHEM RES Inorg. Chem. J. Agric. Food. Chem. J. Chem. Eng. Data J. Chem. Educ. J. Chem. Inf. Model. J. Chem. Theory Comput. J. Med. Chem. J. Nat. Prod. J PROTEOME RES J. Am. Chem. Soc. LANGMUIR MACROMOLECULES Mol. Pharmaceutics Nano Lett. Org. Lett. ORG PROCESS RES DEV ORGANOMETALLICS J. Org. Chem. J. Phys. Chem. J. Phys. Chem. A J. Phys. Chem. B J. Phys. Chem. C J. Phys. Chem. Lett. Analyst Anal. Methods Biomater. Sci. Catal. Sci. Technol. Chem. Commun. Chem. Soc. Rev. CHEM EDUC RES PRACT CRYSTENGCOMM Dalton Trans. Energy Environ. Sci. ENVIRON SCI-NANO ENVIRON SCI-PROC IMP ENVIRON SCI-WAT RES Faraday Discuss. Food Funct. Green Chem. Inorg. Chem. Front. Integr. Biol. J. Anal. At. Spectrom. J. Mater. Chem. A J. Mater. Chem. B J. Mater. Chem. C Lab Chip Mater. Chem. Front. Mater. Horiz. MEDCHEMCOMM Metallomics Mol. Biosyst. Mol. Syst. Des. Eng. Nanoscale Nanoscale Horiz. Nat. Prod. Rep. New J. Chem. Org. Biomol. Chem. Org. Chem. Front. PHOTOCH PHOTOBIO SCI PCCP Polym. Chem.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1